CRL240719P85000
- 0.30
- 0.000.00%
Charles River Newsroom
Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Charles River Laboratories International (CRL) has an average outperform rating and a price target range of $226 to $300, according to analysts polled by Capital IQ.
Charles River (CRAI) Stock Rises 76% Year to Date: Here's How
Those Who Invested in Charles River Laboratories International (NYSE:CRL) Five Years Ago Are up 50%
Charles River Laboratories International, Inc.'s (NYSE:CRL) Intrinsic Value Is Potentially 31% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Charles River Laboratories International fair value estimate is US$265 Charles River Laboratories International's US$203 share price
Is Charles River Associates (CRAI) Outperforming Other Business Services Stocks This Year?
Apple To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Goldman
Express News | Baird Maintains Outperform on Charles River, Lowers Price Target to $239
Baird Maintains Charles River(CRL.US) With Buy Rating, Cuts Target Price to $239
Baird analyst Eric Coldwell maintains $Charles River(CRL.US)$ with a buy rating, and adjusts the target price from $271 to $239.According to TipRanks data, the analyst has a success rate of 53.1%
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Express News | Charles River Laboratories International Inc : Baird Cuts Target Price to $239 From $271
Evercore Maintains Charles River(CRL.US) With Buy Rating, Maintains Target Price $265
Evercore analyst Elizabeth Anderson CFA maintains $Charles River(CRL.US)$ with a buy rating, and maintains the target price at $265.According to TipRanks data, the analyst has a success rate of 37.7%
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Express News | Charles River to Perform Plasmid Manufacturing for Aavantgarde
Charles River to Perform Plasmid Manufacturing for AAVantgarde
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE:CRL) and AAVantgarde today announced a contract
Charles River (CRL) Could Be an Apt Pick Right Now: Here's Why
Charles River Labs Downgraded at Argus on Cautious Biotech Spending
These Nike Analysts Are No Longer Bullish; Here Are Top 5 Downgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Demystifying Charles River: Insights From 4 Analyst Reviews
During the last three months, 4 analysts shared their evaluations of Charles River (NYSE:CRL), revealing diverse outlooks from bullish to bearish.The table below offers a condensed view of their recen
Argus Research Downgrades Charles River(CRL.US) to Hold Rating
Argus Research analyst David Toung downgrades $Charles River(CRL.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 62.0% and a total average return of 9.3% over the p
Charles River Labs Cut to Hold From Buy by Argus Research
Charles River Labs Cut to Hold From Buy by Argus Research